Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

Affiliations

• ¹ Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France.
• ² Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai Health, New York, NY, USA.
• ³ Department of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
• ⁴ Utah Lipid Center, Salt Lake City, UT, USA.
• ⁵ Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
• ⁶ Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA.
• ⁷ Montreal Heart Institute, Université de Montréal, Montreal, Québec, Canada.
• ⁸ Department of Medicine, Baylor College of Medicine, and the Texas Heart Institute, Houston, TX, USA.
• ⁹ FACT (French Alliance for Cardiovascular Trials), Assistance Publique-Hôpitaux de Paris, INSERM Unité 1148, Université Paris-Cité, Hôpital Bichat, Paris, France.